These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27287084)

  • 1. Effect of Extended 30 μg Ethinyl Estradiol with Continuous Low-Dose Ethinyl Estradiol and Cyclic 20 μg Ethinyl Estradiol Oral Contraception on Adolescent Bone Density: A Randomized Trial.
    Gersten J; Hsieh J; Weiss H; Ricciotti NA
    J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):635-642. PubMed ID: 27287084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects on bone mineral density of a monophasic combined oral contraceptive containing nomegestrol acetate/17β-estradiol in comparison to levonorgestrel/ethinylestradiol.
    Sørdal T; Grob P; Verhoeven C
    Acta Obstet Gynecol Scand; 2012 Nov; 91(11):1279-85. PubMed ID: 22762147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
    Skouby SO; Endrikat J; Düsterberg B; Schmidt W; Gerlinger C; Wessel J; Goldstein H; Jespersen J
    Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.
    Teichmann A; Apter D; Emerich J; Greven K; Klasa-Mazurkiewicz D; Melis GB; Spaczynski M; Grubb GS; Constantine GD; Spielmann D
    Contraception; 2009 Dec; 80(6):504-11. PubMed ID: 19913143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women.
    Nappi RE; Paoletti AM; Volpe A; Chiovato L; Howard B; Weiss H; Ricciotti N
    Eur J Contracept Reprod Health Care; 2014 Aug; 19(4):285-94. PubMed ID: 24923685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
    Ahrendt HJ; Makalová D; Parke S; Mellinger U; Mansour D
    Contraception; 2009 Nov; 80(5):436-44. PubMed ID: 19835717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid and biochemical changes after low-dose oral contraception.
    Loke DF; Ng CS; Holck S; Hall PE; Ratnam SS
    Contraception; 1992 Sep; 46(3):227-41. PubMed ID: 1451519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
    Portman DJ; Kaunitz AM; Howard B; Weiss H; Hsieh J; Ricciotti N
    Contraception; 2014 Apr; 89(4):299-306. PubMed ID: 24576794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended regimen of a levonorgestrel/ethinyl estradiol transdermal delivery system: Predicted serum hormone levels using a population pharmacokinetic model.
    Stanczyk FZ; Archer DF; Lohmer LRL; Pirone J; Previtera M; Korner P
    PLoS One; 2022; 17(12):e0279640. PubMed ID: 36574387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens.
    Darwish M; Bond M; Ricciotti N; Hsieh J; Fiedler-Kelly J; Grasela T
    Reprod Sci; 2014 Nov; 21(11):1401-10. PubMed ID: 24647707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol/levonorgestrel combination.
    Heger-Mahn D; Pabst G; Dienel A; Schläfke S; Klipping C
    Drugs R D; 2014 Dec; 14(4):265-72. PubMed ID: 25319228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: a multicenter, randomized, open-label study.
    Chavez A; DelConte A
    Eur J Contracept Reprod Health Care; 1999 Jun; 4(2):75-83. PubMed ID: 10427482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
    Macha S; Mattheus M; Pinnetti S; Woerle HJ; Broedl UC
    Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.
    Archer DF; Jensen JT; Johnson JV; Borisute H; Grubb GS; Constantine GD
    Contraception; 2006 Dec; 74(6):439-45. PubMed ID: 17157099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.
    Gaussem P; Alhenc-Gelas M; Thomas JL; Bachelot-Loza C; Remones V; Ali FD; Aiach M; Scarabin PY
    Thromb Haemost; 2011 Mar; 105(3):560-7. PubMed ID: 21225090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
    Kaunitz AM; Archer DF; Mishell DR; Foegh M
    Am J Obstet Gynecol; 2015 Mar; 212(3):318.e1-8. PubMed ID: 25220709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.
    Seidman L; Kroll R; Howard B; Ricciotti N; Hsieh J; Weiss H
    Contraception; 2015 Jun; 91(6):495-502. PubMed ID: 25746294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.
    Junge W; Mellinger U; Parke S; Serrani M
    Clin Drug Investig; 2011; 31(8):573-584. PubMed ID: 21721593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens.
    Vandever MA; Kuehl TJ; Sulak PJ; Witt I; Coffee A; Wincek TJ; Reape KZ
    Contraception; 2008 Mar; 77(3):162-70. PubMed ID: 18279685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.